The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background: The prevalence of low testosterone levels in men increases with age, as does the prevalence of decreased mobility, sexual function, self-perceived vitality, cognitive abilities, bone mineral density, and glucose tolerance, and of increased anemia and coronary artery disease. Similar changes occur in men who have low serum testosterone concentrations due to known pituitary or testicular disease, and testosterone treatment improves the abnormalities. Prior studies of the effect of testosterone treatment in elderly men, however, have produced equivocal results. Purpose: To describe a coordinated set of clinical trials designed to avoid the pitfalls of prior studies and to determine definitively whether testosterone treatment of elderly men with low testosterone is efficacious in improving symptoms and objective measures of age-associated conditions. Methods: We present the scientific and clinical rationale for the decisions made in the design of this set of trials. Results: We designed The Testosterone Trials as a coordinated set of seven trials to determine if testosterone treatment of elderly men with low serum testosterone concentrations and symptoms and objective evidence of impaired mobility and/or diminished libido and/or reduced vitality would be efficacious in improving mobility (Physical Function Trial), sexual function (Sexual Function Trial), fatigue (Vitality Trial), cognitive function (Cognitive Function Trial), hemoglobin (Anemia Trial), bone density (Bone Trial), and coronary artery plaque volume (Cardiovascular Trial). The scientific advantages of this coordination were common eligibility criteria, common approaches to treatment and monitoring, and the ability to pool safety data. The logistical advantages were a single steering committee, data coordinating center and data and safety monitoring board, the same clinical trial sites, and the possibility of men participating in multiple trials. The major consideration in participant selection was setting the eligibility criterion for serum testosterone low enough to ensure that the men were unequivocally testosterone deficient, but not so low as to preclude sufficient enrollment or eventual generalizability of the results. The major considerations in choosing primary outcomes for each trial were identifying those of the highest clinical importance and identifying the minimum clinically important differences between treatment arms for sample size estimation. Potential limitations: Setting the serum testosterone concentration sufficiently low to ensure that most men would be unequivocally testosterone deficient, as well as many other entry criteria, resulted in screening approximately 30 men in person to randomize one participant. Conclusion: Designing The Testosterone Trials as a coordinated set of seven trials afforded many important scientific and logistical advantages but required an intensive recruitment and screening effort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 1×
“As men age, they also experience decreased muscle mass [3,4] and mobility [5], decreased sexual function [6], decreased energy, anemia [7], decline in memory and other cognitive functions [8], decreased bone mineral density [9] and increased fractures [10], increased fat mass [11], and impaired glucose tolerance [12].”
BackgroundGuralnik, J. M., Ferrucci, L., Pieper, C. F., Leveille, S. G., Markides, K. S., Ostir, G. V., Studenski, S., Berkman, L. F., & Wallace, R. B. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.4.m221 · Cited by 2,898
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 4×
“Cross-sectional studies, such as the European Male Aging Study 1 and longitudinal studies, such as the Baltimore Longitudinal Study of Aging 2 , showed gradual decreases in testosterone with increasing age.”
BackgroundInfluentialPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 1×
“We used the serum total testosterone concentration for screening, even though it is the free testosterone that is biologically active, because assays for total testosterone are more accurate and better standardized than those for free, and usually, total testosterone accurately reflects the free [24].”
MethodSelf-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationA Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464 · cited 1×
“Because metastatic prostate cancer regresses following medical or surgical castration 25 and is exacerbated following testosterone treatment 26 , we excluded men who had a history of prostate cancer or prostatic intraepithelial neoplasia.”
BackgroundGuralnik, J. M., Eisenstaedt, R. S., Ferrucci, L., Klein, H. G., & Woodman, R. C. (2004) · Blood · doi:10.1182/blood-2004-05-1812 · Cited by 1,450
Redelmeier, D. A., Bayoumi, A. M., Goldstein, R. S., & Guyatt, G. H. (1997) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.155.4.9105067 · Cited by 1,029
Wu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939 · cited 3×
“Cross-sectional studies, such as the European Male Aging Study 1 and longitudinal studies, such as the Baltimore Longitudinal Study of Aging 2 , showed gradual decreases in testosterone with increasing age.”
BackgroundBacon, C. G., Mittleman, M. A., Kawachi, I., Giovannucci, E., Glasser, D. B., & Rimm, E. B. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00005 · Cited by 832 · cited 1×
“As men age, they also experience decreased muscle mass [3,4] and mobility [5], decreased sexual function [6], decreased energy, anemia [7], decline in memory and other cognitive functions [8], decreased bone mineral density [9] and increased fractures [10], increased fat mass [11], and impaired glucose tolerance [12].”
BackgroundKatznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 1×
“A prior study showed that testosterone increased volumetric bone mineral density by 9% (standard error 3%) in 1 year [46].”
MethodCowie, C. C., Rust, K. F., Byrd-Holt, D. D., Gregg, E. W., Ford, E. S., Geiss, L. S., Bainbridge, K. E., & Fradkin, J. E. (2010) · Diabetes Care · doi:10.2337/dc09-1524 · Cited by 689 · cited 1×
“As men age, they also experience decreased muscle mass [3,4] and mobility [5], decreased sexual function [6], decreased energy, anemia [7], decline in memory and other cognitive functions [8], decreased bone mineral density [9] and increased fractures [10], increased fat mass [11], and impaired glucose tolerance [12].”
BackgroundAdult lean body mass declines with age: Some longitudinal observations
Forbes, G. B., & Reina, J. C. (1970) · Metabolism · doi:10.1016/0026-0495(70)90062-4 · Cited by 684 · cited 1×
“As men age, they also experience decreased muscle mass [3,4] and mobility [5], decreased sexual function [6], decreased energy, anemia [7], decline in memory and other cognitive functions [8], decreased bone mineral density [9] and increased fractures [10], increased fat mass [11], and impaired glucose tolerance [12].”
BackgroundSrinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629 · cited 2×
“Testosterone treatment consistently increased lean mass and decreased fat mass 13-17 and tended to increase BMD of the spine 18, 19 .”
BackgroundIII, L. J. M., Khosla, S., Crowson, C. S., O'Connor, M. K., O'Fallon, W. M., & Riggs, B. L. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb04719.x · Cited by 598 · cited 1×
“As men age, they also experience decreased muscle mass [3,4] and mobility [5], decreased sexual function [6], decreased energy, anemia [7], decline in memory and other cognitive functions [8], decreased bone mineral density [9] and increased fractures [10], increased fat mass [11], and impaired glucose tolerance [12].”
BackgroundPage, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566
Self-citationAmory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475 · cited 1×
“Testosterone treatment consistently increased lean mass and decreased fat mass [13–17] and tended to increase bone mineral density of the spine [18,19].”
BackgroundSelf-citationRosen, R. C., Allen, K. R., Ni, X., & Araujo, A. B. (2011) · European Urology · doi:10.1016/j.eururo.2011.07.053 · Cited by 460 · cited 1×
“Based on data showing that a change of 4 points in the IIEF is clinically meaningful 45 and that men who are not undergoing treatment do not experience a change, we estimated we would have 90% power to detect if there is a difference in the proportion of men who improve their score by 4 or more…”
BackgroundSelf-citationKenny, A. M., Prestwood, K. M., Gruman, C. A., Marcello, K. M., & Raisz, L. G. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.5.m266 · Cited by 456
Blackman, M. R. (2002) · JAMA · doi:10.1001/jama.288.18.2282 · Cited by 455
Dumurgier, J., Elbaz, A., Ducimetiere, P., Tavernier, B., Alperovitch, A., & Tzourio, C. (2009) · BMJ · doi:10.1136/bmj.b4460 · Cited by 344 · cited 1×
“2 m/s on the 6-min walk test, a value associated with reduced survival [37,38].”
BackgroundLiu, P. Y., Wishart, S. M., & Handelsman, D. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8630 · Cited by 112
Cited by
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Self-citationEstrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone
Budoff, M. J., Ellenberg, S. S., Lewis, C. E., Mohler, E. R., Wenger, N. K., Bhasin, S., Barrett-Connor, E., Swerdloff, R. S., Stephens-Shields, A., Cauley, J. A., et al. (2017) · JAMA · doi:10.1001/jama.2016.21043 · Cited by 376
Self-citationTestosterone and Cardiovascular Disease
Kloner, R. A., Carson, C., Dobs, A., Kopecky, S., & Mohler, E. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.005 · Cited by 371
Self-citationSnyder, P. J., Kopperdahl, D. L., Stephens-Shields, A. J., Ellenberg, S. S., Cauley, J. A., Ensrud, K. E., Lewis, C. E., Barrett-Connor, E., Schwartz, A. V., Lee, D. C., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9539 · Cited by 363
Self-citation
Metadata
- Authors
- Snyder, P. J., Ellenberg, S. S., Cunningham, G. R., Matsumoto, A. M., Bhasin, S., Barrett-Connor, E., Gill, T. M., Farrar, J. T., Cella, D., Rosen, R. C., Resnick, S. M., Swerdloff, R. S., Cauley, J. A., Cifelli, D., Fluharty, L., Pahor, M., Ensrud, K. E., Lewis, C. E., Molitch, M. E., Crandall, J. P., Wang, C., Budoff, M. J., Wenger, N. K., Mohler, E. R., Bild, D. E., Cook, N. L., Keaveny, T. M., Kopperdahl, D. L., Lee, D., Schwartz, A. V., Storer, T. W., Ershler, W. B., Roy, C. N., Raffel, L. J., Romashkan, S., & Hadley, E.
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2014-03-31
- Volume
- 11
- Issue
- 3
- Pages
- 362-375
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W2120668644
- Cited by
- 114
- References
- 23
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.